Some have suggested that a commissioner determined to weaken the efficacy standard need not seek congressional action, but could interpret existing regulations loosely so that requirements for certain clinical trials  —   particularly the costly,   ones that can take years and involve thousands of patients   —   can be rolled back. That could have serious implications for patients. Last month, the F. D. A. released a study of 22 drugs that appeared promising in early studies but failed in final,   trials. 